Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Неалкогольная жировая болезнь печени: возможности лечения фитопрепаратами
Неалкогольная жировая болезнь печени: возможности лечения фитопрепаратами
Аникин Г.С. Неалкогольная жировая болезнь печени: возможности лечения фитопрепаратами. Consilium Medicum. Гастроэнтерология (Прил.). 2015; 2: 15–18.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В период эпидемии неалкогольной жировой болезни печени особенно актуальным является ее лечение для профилактики не только сердечно-сосудистых заболеваний, но и хронической болезни почек. Основной задачей лечения неалкогольной жировой болезни печени становится предотвращение развития цирроза печени. Препарат Гепабене широко применяется для решения этой задачи. В обзорной статье приведены данные клинических исследований, подтверждающих эффективность и безопасность Гепабене.
Ключевые слова: неалкогольная жировая болезнь печени, цирроз печени, препарат Гепабене.
Key words: nonalcoholic fatty liver disease, cirrhosis, Hepabene.
Ключевые слова: неалкогольная жировая болезнь печени, цирроз печени, препарат Гепабене.
________________________________________________
Key words: nonalcoholic fatty liver disease, cirrhosis, Hepabene.
Полный текст
Список литературы
1. Omagari K, Kadokawa Y, Masuda J et al. Fatty liver in non-alcoholic non overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002; p. 1098–105.
2. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population – examinations of 503 consecutive fatal traffi c casualties. Scand J Gastroenterol 1977; 12 (5): 593–7.
3. Shen L, Fan JG, Shao Y et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9: 1106–10.
4. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903. РЖГГК. 2014; 24 (4): 32–8. / Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogol'noi zhirovoi bolezni pecheni v Rossii (Rezul'taty otkrytogo mnogotsentrovogo prospektivnogo issledovaniia-nabliudeniia DIREG L 01903. RZhGGK. 2014; 24 (4): 32–8. [in Russian]
5. Laxmi MV, Mouen K, Naga Ch. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009, 11: 50–5.
6. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9 (7): 372–81.
7. Williams T. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease. FP Essent 2015; 435: 24–9.
8. Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. Med Sci Monit 2006; 12 (1): RA23-6.
9. Preisig R. Supplements to the editorial “Liver protection therapy”. Schweiz Rundsch Med Prax 1970; 59: 1559–60.
10. Оковитый С.В., Безбородкина Н.Н., Улейчик С.Г., Шуленин С.Н. Гепатопротекторы. М.: ГЭОТАР-Медиа, 2010. / Okovityi S.V., Bezborodkina N.N., Uleichik S.G., Shulenin S.N. Gepatoprotektory. M.: GEOTAR-Media, 2010. [in Russian]
11. Seeff LB, Curto TM, Szabo G et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47 (2): 605–12.
12. Feher J, Deak G, Muzes G et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1989; 130 (51): 2723–7.
13. Hashemi SJ, Hajiani E, Sardabi EH. A placebocontrolled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009; 9 (4): 265–70.
14. Rambaldi A, Bradly PJ, Iaquinto G et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100 (11): 2583–91.
15. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9 (1): 105–13.
16. Velussi M, Cernigoi AM, De Monte A et al. Longterm (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26 (4): 871–9.
17. Маев И.В., Дичева Д.Т., Андреев Д.Н., Гуртовенко И.Ю. Применение препарата Гепабене в терапии бескаменного холецистита. Consilium Medicum. 2012; 14 (8): 36–40. / Maev I.V., Dicheva D.T., Andreev D.N., Gurtovenko I.Iu. Primenenie preparata Gepabene v terapii beskamennogo kholetsistita. Consilium Medicum. 2012; 14 (8): 36–40. [in Russian]
18. Инструкция по применению лекарственного препарата Гепабене. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=29183&t= / Instruktsiia po primeneniiu lekarstvennogo preparata Gepabene. http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?idReg=29183&t= [in Russian]
2. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population – examinations of 503 consecutive fatal traffi c casualties. Scand J Gastroenterol 1977; 12 (5): 593–7.
3. Shen L, Fan JG, Shao Y et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9: 1106–10.
4. Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogol'noi zhirovoi bolezni pecheni v Rossii (Rezul'taty otkrytogo mnogotsentrovogo prospektivnogo issledovaniia-nabliudeniia DIREG L 01903. RZhGGK. 2014; 24 (4): 32–8. [in Russian]
5. Laxmi MV, Mouen K, Naga Ch. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009, 11: 50–5.
6. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9 (7): 372–81.
7. Williams T. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease. FP Essent 2015; 435: 24–9.
8. Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. Med Sci Monit 2006; 12 (1): RA23-6.
9. Preisig R. Supplements to the editorial “Liver protection therapy”. Schweiz Rundsch Med Prax 1970; 59: 1559–60.
10. Okovityi S.V., Bezborodkina N.N., Uleichik S.G., Shulenin S.N. Gepatoprotektory. M.: GEOTAR-Media, 2010. [in Russian]
11. Seeff LB, Curto TM, Szabo G et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47 (2): 605–12.
12. Feher J, Deak G, Muzes G et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1989; 130 (51): 2723–7.
13. Hashemi SJ, Hajiani E, Sardabi EH. A placebocontrolled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009; 9 (4): 265–70.
14. Rambaldi A, Bradly PJ, Iaquinto G et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100 (11): 2583–91.
15. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9 (1): 105–13.
16. Velussi M, Cernigoi AM, De Monte A et al. Longterm (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26 (4): 871–9.
17. Maev I.V., Dicheva D.T., Andreev D.N., Gurtovenko I.Iu. Primenenie preparata Gepabene v terapii beskamennogo kholetsistita. Consilium Medicum. 2012; 14 (8): 36–40. [in Russian]
18. Instruktsiia po primeneniiu lekarstvennogo preparata Gepabene. http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?idReg=29183&t= [in Russian]
2. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population – examinations of 503 consecutive fatal traffi c casualties. Scand J Gastroenterol 1977; 12 (5): 593–7.
3. Shen L, Fan JG, Shao Y et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9: 1106–10.
4. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903. РЖГГК. 2014; 24 (4): 32–8. / Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogol'noi zhirovoi bolezni pecheni v Rossii (Rezul'taty otkrytogo mnogotsentrovogo prospektivnogo issledovaniia-nabliudeniia DIREG L 01903. RZhGGK. 2014; 24 (4): 32–8. [in Russian]
5. Laxmi MV, Mouen K, Naga Ch. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009, 11: 50–5.
6. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9 (7): 372–81.
7. Williams T. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease. FP Essent 2015; 435: 24–9.
8. Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. Med Sci Monit 2006; 12 (1): RA23-6.
9. Preisig R. Supplements to the editorial “Liver protection therapy”. Schweiz Rundsch Med Prax 1970; 59: 1559–60.
10. Оковитый С.В., Безбородкина Н.Н., Улейчик С.Г., Шуленин С.Н. Гепатопротекторы. М.: ГЭОТАР-Медиа, 2010. / Okovityi S.V., Bezborodkina N.N., Uleichik S.G., Shulenin S.N. Gepatoprotektory. M.: GEOTAR-Media, 2010. [in Russian]
11. Seeff LB, Curto TM, Szabo G et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47 (2): 605–12.
12. Feher J, Deak G, Muzes G et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1989; 130 (51): 2723–7.
13. Hashemi SJ, Hajiani E, Sardabi EH. A placebocontrolled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009; 9 (4): 265–70.
14. Rambaldi A, Bradly PJ, Iaquinto G et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100 (11): 2583–91.
15. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9 (1): 105–13.
16. Velussi M, Cernigoi AM, De Monte A et al. Longterm (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26 (4): 871–9.
17. Маев И.В., Дичева Д.Т., Андреев Д.Н., Гуртовенко И.Ю. Применение препарата Гепабене в терапии бескаменного холецистита. Consilium Medicum. 2012; 14 (8): 36–40. / Maev I.V., Dicheva D.T., Andreev D.N., Gurtovenko I.Iu. Primenenie preparata Gepabene v terapii beskamennogo kholetsistita. Consilium Medicum. 2012; 14 (8): 36–40. [in Russian]
18. Инструкция по применению лекарственного препарата Гепабене. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=29183&t= / Instruktsiia po primeneniiu lekarstvennogo preparata Gepabene. http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?idReg=29183&t= [in Russian]
________________________________________________
2. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population – examinations of 503 consecutive fatal traffi c casualties. Scand J Gastroenterol 1977; 12 (5): 593–7.
3. Shen L, Fan JG, Shao Y et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9: 1106–10.
4. Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogol'noi zhirovoi bolezni pecheni v Rossii (Rezul'taty otkrytogo mnogotsentrovogo prospektivnogo issledovaniia-nabliudeniia DIREG L 01903. RZhGGK. 2014; 24 (4): 32–8. [in Russian]
5. Laxmi MV, Mouen K, Naga Ch. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009, 11: 50–5.
6. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9 (7): 372–81.
7. Williams T. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease. FP Essent 2015; 435: 24–9.
8. Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. Med Sci Monit 2006; 12 (1): RA23-6.
9. Preisig R. Supplements to the editorial “Liver protection therapy”. Schweiz Rundsch Med Prax 1970; 59: 1559–60.
10. Okovityi S.V., Bezborodkina N.N., Uleichik S.G., Shulenin S.N. Gepatoprotektory. M.: GEOTAR-Media, 2010. [in Russian]
11. Seeff LB, Curto TM, Szabo G et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47 (2): 605–12.
12. Feher J, Deak G, Muzes G et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1989; 130 (51): 2723–7.
13. Hashemi SJ, Hajiani E, Sardabi EH. A placebocontrolled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009; 9 (4): 265–70.
14. Rambaldi A, Bradly PJ, Iaquinto G et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100 (11): 2583–91.
15. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9 (1): 105–13.
16. Velussi M, Cernigoi AM, De Monte A et al. Longterm (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26 (4): 871–9.
17. Maev I.V., Dicheva D.T., Andreev D.N., Gurtovenko I.Iu. Primenenie preparata Gepabene v terapii beskamennogo kholetsistita. Consilium Medicum. 2012; 14 (8): 36–40. [in Russian]
18. Instruktsiia po primeneniiu lekarstvennogo preparata Gepabene. http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?idReg=29183&t= [in Russian]
Авторы
Г.С.Аникин*
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
ФГБУ Поликлиника №3 Управления делами Президента РФ. 129090, Россия, Москва, пер. Грохольский, д. 31
*medi321@mail.ru
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
Out-Patient Сlinic №3 of Administration of the President of the Russian Federation. 129090, Russian Federation, Moscow, per. Grokhol'skii, d. 31
*medi321@mail.ru
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
ФГБУ Поликлиника №3 Управления делами Президента РФ. 129090, Россия, Москва, пер. Грохольский, д. 31
*medi321@mail.ru
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
Out-Patient Сlinic №3 of Administration of the President of the Russian Federation. 129090, Russian Federation, Moscow, per. Grokhol'skii, d. 31
*medi321@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.